TCRTHealthcare · BiotechnologyTCRT Stock Forecast: Alaunos Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half.
TCRT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Alaunos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Alaunos Therapeutics, Inc. — and when they’d sell — is the membership.
TCRT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TCRT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Aug 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 Aug 2023 | Laidlaw & Co. | Downgrade | Hold | — |
| 15 May 2023 | HC Wainwright & Co. | Upgrade | Buy | $1.50 |
| 27 Mar 2023 | Wells Fargo | Assumes | Overweight | $3.00 |
| 4 Oct 2022 | Wells Fargo | Assumes | Overweight | $3.00 |
| 15 July 2022 | Cantor Fitzgerald | Assumes | Overweight | $3.00 |
| 4 May 2022 | Wells Fargo | Upgrade | Overweight | $3.00 |
| 9 Nov 2021 | Raymond James | Maintains | Market Perform | — |
| 10 Aug 2021 | Raymond James | Downgrade | Market Perform | — |
| 7 May 2021 | Raymond James | Maintains | Outperform | — |
| 12 Mar 2021 | Jefferies | Downgrade | Hold | — |
| 1 Mar 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 19 June 2020 | Jefferies | Initiates | Buy | — |
| 11 May 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2020 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 Mar 2020 | Raymond James | Maintains | Outperform | — |
| 4 Apr 2019 | Lake Street | Initiates | Buy | — |
| 1 Apr 2019 | Laidlaw & Co. | Initiates | Buy | — |
| 15 Nov 2018 | Raymond James | Upgrade | Outperform | — |
| 18 June 2018 | JP Morgan | Downgrade | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TCRT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Alaunos Therapeutics, Inc. (TCRT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.9×
- Price / sales
- 1530.4×
- Price / book
- 3.5×
- EV / EBITDA
- −1.0×
Cheaper than 81% of US stocks
Cheaper than 1% of US stocks
Cheaper than 30% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −138166.7%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −350.3%
- Return on assets
- −129.4%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TCRT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TCRT appears on the weeks it earns a place.
Frequently asked questions about TCRT stock
How does Ticker Nerd's model rank TCRT?
As at 1 Aug 2026, Alaunos Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the TCRT stock forecast for 2030?
No analyst covering Alaunos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TCRT are extrapolating price history, which says nothing about the business.
How has TCRT stock performed over the past year?
Alaunos Therapeutics, Inc. returned -30.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alaunos Therapeutics, Inc. do?
Alaunos Therapeutics Inc. is a biotechnology company focused on the development of innovative cell therapies to treat various forms of cancer.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc. is a biotechnology company focused on the development of innovative cell therapies to treat various forms of cancer. Committed to advancing the field of oncology, its primary function is to harness the power of the immune system by engineering T-cells to target and eradicate cancer cells. Key features of Alaunos Therapeutics' approach include cutting-edge technologies like its proprietary library of TCRs (T-cell receptors) which are designed to enhance precision in targeting cancerous mutations. This capability positions the company at the forefront of immunotherapy research and development, particularly in its impact on solid tumors and hematological malignancies. Operating within a highly specialized industry, Alaunos Therapeutics plays a critical role in the biomedical sector by contributing to the development of next-generation treatments that aim to provide new hope for patients whose options may be limited by traditional therapies. Headquartered in the United States, it continues to collaborate with leading institutions to push the boundaries of cancer treatment through innovative scientific solutions.
CEO Mr. Holger Weis CPA · 1 employees · United States · https://www.alaunos.com